Q2 FY2026 EarningsQ2 FY26 beat consensus significantly across all key metrics: revenue of $129.9M vs. $118.9M expected (+9.26%), and GAAP EPS of $0.11 vs. $0.03 expected. ZORYVE net product sales grew 59% YoY, driven by strong demand and improved gross-to-net pricing. Management raised full-year FY26 sales guidance to $525M–$540M, well above previous ranges, signaling sustained commercial momentum in the dermatology market.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Arcutis Biotherapeutics(ARQT) the Revenue is 129.86 M (+59.33%), Beat estimate;the EBIT is 16.43 M (+212.4%), Beat estimate;the EPS is 0.11 (+184.6%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.13B59.33%
0.12B45.82%
+0.01B13.51%
EBITExceed expectations
0.02B212.44%
0.00B123.92%
+0.01B88.52%
EPSExceed expectations
0.11184.62%
0.0283121.79%
+0.081762.83%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf